The Weight Loss Heavyweights Still Lead the GLP-1 Revolution

January 23, 2025
You must provide your professional email address to view this content.

For every study highlighting potential concerns for GLP-1 medicines, multiple others reveal promising new applications, from metabolic disorders to addiction treatment. The breadth of positive clinical evidence suggests these medications will deliver substantial societal benefits for years to come. At current levels, both Novo Nordisk and Eli Lilly offer investors exposure to what we believe will be one of healthcare’s most significant innovations of the decade—an opportunity that has become more attractively priced without any fundamental deterioration in long-term growth prospects.

Disclaimer / Securities Disclosure

The author(s) of this research note do (does) not personally hold a any position in any of the above-mentioned securities.
Nordis Capital (SMS’ sister company) holds long positions in Novo Nordisk, Eli Lilly and Structure Therapeutics in its ESG funds.

DISCLAIMER
© Sustainable Market Strategies, a division of SMS Financial Technologies inc. Redistribution prohibited without prior consent. This report has been prepared by Sustainable Market Strategies mainly for distribution to market professionals and institutional investors. It should not be considered as investment advice or a recommendation to purchase any particular security, strategy, or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.